Overview

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study evaluated the safety and efficacy of once and twice daily TD-4208 and placebo when administered using a jet nebulizer for 7 days in a cross-over design to patients with moderate to severe chronic obstructive pulmonary disease.
Phase:
Phase 2
Details
Lead Sponsor:
Mylan Inc.
Theravance Biopharma R & D, Inc.
Collaborator:
Theravance Biopharma